{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:25:43Z","timestamp":1760059543300,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research (KAKENHI)","doi-asserted-by":"publisher","award":["20K10354"],"award-info":[{"award-number":["20K10354"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Yellow fever (YF) is an acute hemorrhagic zoonotic disease that causes severe liver damage, renal failure, and hemorrhagic shock. No antiviral treatment is available; thus, vaccination is a critical preventive measure. Although the World Health Organization (WHO) revised the guidelines regarding the need for booster vaccination for YF with the rationale that a single vaccination provides sufficient long-term immunogenicity, no studies have evaluated long-term immunity in Japanese adults who received a single dose of YF vaccine. This study evaluated the long-term persistence of immunogenicity in Japanese adults vaccinated with the YF vaccine. This observational study enrolled Japanese adults who received a single YF vaccination &gt;5 years previously. Blood samples were collected after confirming eligibility for the study. The serum levels of anti-yellow fever virus (YFV)-neutralizing antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). The 65 participants comprised 35 males and 30 females, with a median age at vaccination of 34 years. The time between YF vaccination and registration was between 5 and 26 years. All participants remained seropositive even after a long time. Statistical analysis showed no correlation between the time elapsed since YF vaccination and PRNT50. Our results indicate that a single dose of YF vaccine provides adequate long-term immunity in Japanese adults and that booster vaccinations are not routinely required. These findings strongly aid in the development of travel medicine guidelines and the optimization of vaccination strategies by reducing the usage of medical resources and simplifying the health requirements for travelers.<\/jats:p>","DOI":"10.3390\/vaccines13070675","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:44:41Z","timestamp":1750761881000},"page":"675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-610X","authenticated-orcid":false,"given":"Shinji","family":"Fukushima","sequence":"first","affiliation":[{"name":"Travellers\u2019 Medical Center, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku 160-0023, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-8300","authenticated-orcid":false,"given":"Chang Kweng","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku 162-8640, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-9959","authenticated-orcid":false,"given":"Atsuo","family":"Hamada","sequence":"additional","affiliation":[{"name":"Travellers\u2019 Medical Center, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku 160-0023, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref_1","unstructured":"WHO (2025, May 17). Fact Sheet: Yellow Fever, WHO. 31 May 2023, Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs100\/en\/."},{"key":"ref_2","unstructured":"WHO (2025, May 17). Countries with Risk of Yellow Fever Transmission and Countries Requiring Yellow Fever Vaccination (November 2022), Available online: https:\/\/www.who.int\/publications\/m\/item\/countries-with-risk-of-yellow-fever-transmission-and-countries-requiring-yellow-fever-vaccination-(november-2022)."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Servadio, J.L., Mu\u00f1oz-Zanzi, C., and Convertino, M. (2021). Estimating case fatality risk of severe Yellow Fever cases: Systematic literature review and meta-analysis. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06535-4"},{"key":"ref_4","first-page":"1","article-title":"Yellow fever vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_5","unstructured":"WHO (2013). Vaccines and vaccination against yellow fever. WHO position paper\u2014June 2013. Wkly. Epidemiol. Rec., 88, 269\u2013283."},{"key":"ref_6","unstructured":"WHO (2025, May 17). Q&A on the Extension to Life for Yellow Fever Vaccination, Available online: https:\/\/www.who.int\/publications\/m\/item\/q-a-on-the-extension-to-life-for-yellow-fever-vaccination."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_8","first-page":"647","article-title":"Yellow fever vaccine booster doses: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","article-title":"Booster dose after 10 years is recommended following 17DD-YF primary vaccination","volume":"12","author":"Antonelli","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"tay130","DOI":"10.1093\/jtm\/tay130","article-title":"Ten yearly yellow fever booster vaccinations may still be justified","volume":"25","author":"Plotkin","year":"2018","journal-title":"J. Travel. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.vaccine.2023.03.022","article-title":"Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults","volume":"41","author":"Faggioni","year":"2023","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"126083","DOI":"10.1016\/j.vaccine.2024.06.050","article-title":"Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study\u2014A complementary study","volume":"42","author":"Vianna","year":"2024","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.11150\/kansenshogakuzasshi1970.76.738","article-title":"Antibody responses in Japanese volunteers after immunization with yellow fever vaccine","volume":"76","author":"Taga","year":"2002","journal-title":"Kansenshogaku Zasshi J. Jpn. Assoc. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","article-title":"Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: A randomized trial","volume":"38","author":"Camacho","year":"2004","journal-title":"Rev. Saude Publica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0264-410X(98)00487-3","article-title":"Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates","volume":"17","author":"Monath","year":"1999","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e0151623","DOI":"10.1128\/jvi.01516-23","article-title":"Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination","volume":"98","author":"Mantel","year":"2024","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jiac.2023.01.015","article-title":"Analysis of cross-reactivity among flaviviruses using sera of patients with dengue showed the importance of neutralization tests with paired serum samples for the correct interpretations of serological test results for dengue","volume":"29","author":"Maeki","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/CVI.00396-09","article-title":"Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcgamma receptor (FcgammaR)-negative and FcgammaR-expressing BHK-21 cells","volume":"17","author":"Moi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.7883\/yoken.JJID.2023.290","article-title":"Long-term immunity after vaccination against yellow fever in Korean travelers","volume":"78","author":"Um","year":"2025","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"ref_25","first-page":"282ra48","article-title":"Long-lasting stem cell\u2013like memory CD8+ T cells with a na\u00efve-like profile upon yellow fever vaccination","volume":"7","author":"Soneson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.lanmic.2024.06.004","article-title":"Yellow fever breakthrough infections after yellow fever vaccination: A systematic review and meta-analysis","volume":"5","author":"Schnyder","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum. Vaccin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"taab126","DOI":"10.1093\/jtm\/taab126","article-title":"Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study","volume":"28","author":"Rosenstein","year":"2021","journal-title":"J. Travel. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.vaccine.2019.12.042","article-title":"Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals","volume":"38","author":"Burkhard","year":"2020","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.vaccine.2015.03.069","article-title":"Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?","volume":"33","author":"Michel","year":"2015","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2016.12.003","article-title":"Yellow fever vaccination -Once in a lifetime?","volume":"15","author":"Grobusch","year":"2017","journal-title":"Travel. Med. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"tay134","DOI":"10.1093\/jtm\/tay134","article-title":"Waning immunity after single-dose yellow fever vaccination: Who needs a second shot?","volume":"26","author":"Visser","year":"2019","journal-title":"J. Travel. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/infdis\/jiz374","article-title":"Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting","volume":"221","author":"Kareko","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD Yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil","volume":"25","author":"Antonelli","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: A systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_37","unstructured":"Centers for Disease Control and Prevention (2025, May 17). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Yellow Fever Vaccine Booster Doses, Available online: https:\/\/www.cdc.gov\/acip\/grade\/yf-vac-boost.html."},{"key":"ref_38","unstructured":"WHO (2025, May 17). For Further Information on the EYE Initiative, Available online: https:\/\/www.who.int\/initiatives\/eye-strategy#:~:text=The%20EYE%20strategy%20is%20a,prevent%20international%20spread%3B%20and."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:57:57Z","timestamp":1760032677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["vaccines13070675"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13070675","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}